These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1837757)

  • 1. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia.
    De Keyser J
    Clin Neuropharmacol; 1991 Dec; 14(6):562-5. PubMed ID: 1837757
    [No Abstract]   [Full Text] [Related]  

  • 2. Tardive dyskinesia: a role for the endogenous opioid system.
    Sandyk R
    Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the biochemical pharmacology of extrapyramidal movement disorders.
    Klawans HL; Goetz C; Nausieda PA; Weiner WJ
    Adv Exp Med Biol; 1977; 90():21-47. PubMed ID: 145167
    [No Abstract]   [Full Text] [Related]  

  • 4. Mesolimbic system and tardive dyskinesia: new perspectives for therapy.
    Cools AR
    Mod Probl Pharmacopsychiatry; 1983; 21():111-23. PubMed ID: 6140628
    [No Abstract]   [Full Text] [Related]  

  • 5. 17 beta-Estradiol may affect vulnerability of striatum in a 3-nitropropionic acid-induced experimental model of Huntington's disease in ovariectomized rats.
    Túnez I; Collado JA; Medina FJ; Peña J; Del C Muñoz M; Jimena I; Franco F; Rueda I; Feijóo M; Muntané J; Montilla P
    Neurochem Int; 2006 Apr; 48(5):367-73. PubMed ID: 16420966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
    Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
    Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive changes in brain dopamine function as a result of neuroleptic treatment.
    Jenner P; Marsden CD
    Adv Neurol; 1988; 49():417-31. PubMed ID: 2894127
    [No Abstract]   [Full Text] [Related]  

  • 8. The basal ganglia in extrapyramidal dysfunction.
    Barnes CD
    Brain Res Bull; 1983 Aug; 11(2):271-5. PubMed ID: 6226339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia.
    Brotchie JM
    Adv Neurol; 1999; 80():71-85. PubMed ID: 10410705
    [No Abstract]   [Full Text] [Related]  

  • 10. Apomorphine-induced dyskinesias after excitotoxic caudate-putamen lesions and the effects of neural transplantation in non-human primates.
    Isacson O; Hantraye P; Maziere M; Sofroniew MV; Riche D
    Prog Brain Res; 1990; 82():523-33. PubMed ID: 2149770
    [No Abstract]   [Full Text] [Related]  

  • 11. The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats.
    Andreassen OA; Finsen B; Ostergaard K; Sørensen JC; West MJ; Jørgensen HA
    Neuroscience; 1999 Jan; 88(1):27-35. PubMed ID: 10051187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible cholinergic mechanism in reserpine and tardive dyskinesia.
    Dilsaver SC; Greden JF
    Am J Psychiatry; 1984 Jan; 141(1):151-2. PubMed ID: 6691448
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of GABA in dyskinesias induced by chemical stimulation of the striatum.
    Standefer MJ; Dill RE
    Life Sci; 1977 Nov; 21(10):1515-20. PubMed ID: 927013
    [No Abstract]   [Full Text] [Related]  

  • 14. Neuroleptic-induced respiratory dyskinesia.
    Kruk J; Sachdev P; Singh S
    J Neuropsychiatry Clin Neurosci; 1995; 7(2):223-9. PubMed ID: 7626967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schizophrenia and tardive dyskinesia: is schizophrenia also a "denervation hypersensitivity"?
    Kapit RM
    Med Hypotheses; 1977; 3(5):207-10. PubMed ID: 904502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic-induced tardive dyskinesia.
    Jenner P; Marsden CD
    Acta Psychiatr Belg; 1987; 87(5):566-98. PubMed ID: 2897761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The endocrinology of extrapyramidal system disorders.
    Kirkpatrick B; Tamminga CA
    Endocrinol Metab Clin North Am; 1988 Mar; 17(1):159-72. PubMed ID: 2967753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease, Huntington's disease and tardive dyskinesia. Neurochemical pathology and treatment.
    Tolosa ES
    Minn Med; 1979 Feb; 62(2):101-6. PubMed ID: 155195
    [No Abstract]   [Full Text] [Related]  

  • 20. Voluntary movement dysfunction in Huntington's disease and tardive dyskinesia.
    David AS; Jeste DV; Folstein MF; Folstein SE
    Acta Neurol Scand; 1987 Feb; 75(2):130-9. PubMed ID: 2883804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.